MedTrace Logo

Reverse Transcriptase Inhibitors in AGS

NCT02363452 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2025-09-05

No results posted yet for this study

Summary

The purpose of this study is to determine if treatment with reverse transcriptase inhibitors returns the interferon signature observed in patients with AGS to normal levels.

Conditions

  • Aicardi-Goutières Syndrome (AGS)

Interventions

DRUG

Reverse transcriptase inhibitors: Zidovudine, Lamivudine, Abacavir

Oral Solution (syrup) or Tablets

Sponsors & Collaborators

  • URC-CIC Paris Descartes Necker Cochin

    collaborator OTHER

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Yanick CROW, MD, PhD · Hôpital Necker - Enfants Malades Public Hospitals of Paris

  • Stéphane BLANCHE, MD,PhD · Hôpital Necker - Enfants Malades Public Hospitals of Paris

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Month
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-10
Primary Completion
2018-01-31
Completion
2018-06-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02363452 on ClinicalTrials.gov